GOLD 2025 — Global Strategy for Prevention, Diagnosis and Management of COPD

1. Definition

2. Diagnosis

Spirometry (required for diagnosis)

Airflow Limitation Severity (GOLD Grades)

3. Symptom & Risk Assessment

Symptom Tools

• mMRC Dyspnea Scale (0–4)
• CAT™ Score (0–40; ≥10 = significant symptoms)

Combined Assessment: ABE Classification (introduced GOLD 2023, retained 2025)

4. Initial Pharmacological Treatment

Blood Eosinophil Count as ICS Guide

• Eos < 100/µL: ICS unlikely to benefit; avoid
• Eos 100–300/µL: Consider ICS if frequent exacerbations
• Eos ≥ 300/µL: ICS strongly favored

5. Follow-up / Escalation Treatment

• Persistent dyspnea on monotherapy → Escalate to LABA + LAMA
• Persistent exacerbations on LABA + LAMA → Add ICS (LABA + LAMA + ICS triple therapy)
• Persistent exacerbations on triple therapy → Consider roflumilast (FEV₁ < 50%, chronic bronchitis phenotype) or azithromycin (ex-smoker)

6. Management of Exacerbations

Definition

Severity Classification

Pharmacological Treatment (Global Strategy for Prevention, Diagnosis and Management of COPD 2025, p. 128)

1. Bronchodilators — SABD (SABA ± SAMA) are first-line; increase dose/frequency
2. Systemic corticosteroids — Prednisolone 40 mg/day × 5 days; shortens recovery, reduces treatment failure
3. Antibiotics — Indicated when sputum purulence is present or patient requires mechanical ventilation; amoxicillin, doxycycline, or macrolides typically used; guided by local resistance patterns

Non-Pharmacological

• Controlled oxygen therapy (target SpO₂ 88–92%)
• Non-invasive ventilation (NIV) for hypercapnic respiratory failure (pH < 7.35)
• Invasive mechanical ventilation if NIV fails or contraindicated

7. Non-Pharmacological Management

8. Surgical & Interventional Options

• Lung volume reduction surgery (LVRS): Upper-lobe emphysema + low exercise capacity after rehab
• Bronchoscopic lung volume reduction (BLVR): Endobronchial valves (Zephyr) for heterogeneous emphysema with intact fissures
• Lung transplantation: Selected very severe COPD patients

9. COPD & Comorbidities

• Cardiovascular disease (most common cause of death)
• Anxiety and depression
• Osteoporosis
• Lung cancer
• Obstructive sleep apnea
• Type 2 diabetes

10. Key Updates in GOLD 2025 vs Prior Years

• Continued emphasis on treatable traits and precision medicine
• Blood eosinophils as a biomarker guiding ICS use (refined thresholds)
• Strengthened recommendation for dual bronchodilation (LABA + LAMA) as initial therapy for Group B
• Updated exacerbation definition with clearer severity stratification
• Expanded vaccination recommendations (RSV added)
• Recognition of COPD in non-smokers, women, and low/middle-income countries

Note: The GOLD 2026 Report is expected to be released in late 2025/early 2026. Until its official publication, GOLD 2025 remains the current standard. Check goldcopd.org for the latest release.

GOLD 2026 Pocket Guide: Comprehensive Summary

1. Definition & Overview

• Epidemiology: Top 3 cause of death worldwide; >3 million deaths in 2021 (5% of global deaths); 90% in LMICs
• Pathogenesis (GETomics): Gene × Environment × Time interactions — tobacco smoke, household/outdoor air pollution, occupational exposures, abnormal lung development, accelerated aging
• Etiotypes (GOLD 2026 taxonomy):

2. Diagnosis & Assessment

Diagnostic Criteria

• Post-bronchodilator FEV₁/FVC < 0.7 confirms diagnosis
• Pre-BD spirometry can exclude COPD (if FEV₁/FVC ≥ 0.7 pre-BD, COPD is unlikely)
• Consider diagnosis in patients with: progressive dyspnea, recurrent wheeze, chronic cough, recurrent lower RTIs, history of risk factor exposure

GOLD Airflow Obstruction Grades (post-BD FEV₁)

ABE Symptom/Risk Classification

• Group A: 0 moderate/severe exacerbations in prior year + low symptoms (mMRC 0–1, CAAT < 10)
• Group B: 0 moderate/severe exacerbations + high symptoms (mMRC ≥ 2, CAAT ≥ 10)
• Group E: ≥ 1 moderate or severe exacerbation in prior year (regardless of symptoms)

Symptom Tools

• mMRC scale (0–4): Grades dyspnea severity
• CAAT™ (Chronic Airways Assessment Test): 8-item questionnaire, scores 0–40; ≥ 10 = significant symptom burden

CT Indications in Stable COPD

• Differential diagnosis (bronchiectasis, atypical infections)
• Lung volume reduction candidate evaluation (post-BD FEV₁ 15–45%, hyperinflation evidence)
• Annual low-dose CT for lung cancer screening (smoking history, per general population guidelines)

3. Prevention & Management of Stable COPD

Treatment Goals

1. Reduce symptoms: relieve dyspnea, improve exercise tolerance, improve health status
2. Reduce risk: prevent disease progression, prevent/treat exacerbations, reduce mortality

Non-Pharmacological (Essential)

• Smoking cessation — most impactful intervention (Evidence A); varenicline, NRT, bupropion are first-line pharmacotherapy; no current evidence supports e-cigarettes as cessation aids
• Physical activity — strongly encouraged in all patients
• Pulmonary rehabilitation — indicated for Groups B and E; improves dyspnea, exercise capacity, QoL, reduces hospitalizations
• Vaccinations:
  • Influenza (yearly) — Evidence B
  • COVID-19 (per national recommendations) — Evidence B
  • Pneumococcal (PCV21 or PCV20) — Evidence B
  • RSV vaccine (age ≥ 50, or with chronic heart/lung disease) — Evidence A
  • Tdap/dTaP (if not vaccinated in adolescence) — Evidence B
  • Zoster vaccine (age > 50) — Evidence B

Initial Pharmacological Treatment

ICS Use — Blood Eosinophil Guidance

Follow-up / Escalation Pharmacotherapy

• Escalate to LABA + LAMA
• Consider ensifentrine (new PDE3/PDE4 inhibitor — improves FEV₁, dyspnea, health status; Evidence A)
• Investigate and treat other causes of dyspnea

• Add ICS (guided by eosinophils) → triple therapy (LABA+LAMA+ICS)
• If still exacerbating on triple therapy:
  • Roflumilast (if FEV₁ < 50% + chronic bronchitis)
  • Azithromycin (preferentially in former smokers)
  • Biologic therapy (if eos ≥ 300 cells/µL):
    • Dupilumab (chronic bronchitis phenotype) — reduces exacerbations, improves FEV₁ (Evidence A)
    • Mepolizumab — reduces exacerbations (Evidence A)

Patients Currently on LABA+ICS

• No exacerbation history + low symptoms → consider switching to LABA+LAMA
• Current exacerbations + eos ≥ 100 → consider escalating to LABA+LAMA+ICS
• Current exacerbations + eos < 100 → consider LABA+LAMA

Oxygen Therapy (Stable COPD)

• LTOT indicated when: PaO₂ ≤ 55 mmHg, or PaO₂ 56–60 mmHg with cor pulmonale or polycythemia — improves survival (Evidence A)
• LTOT not routinely indicated for moderate resting or exercise-induced desaturation (Evidence A)
• Prescribe to maintain SaO₂ ≥ 90%; reassess at 60–90 days

Ventilatory Support (Stable)

• Long-term NIV (NPPV): Consider in severe chronic hypercapnia (PaCO₂ > 53 mmHg) + recent hospitalization — may improve hospitalization-free survival (Evidence B)

4. Surgical & Interventional Therapies

5. Management of Exacerbations

Definition

Severity Classification (Rome Proposal)

Pharmacological Treatment

• Short-acting bronchodilators (SABA ± SAMA): first-line (Evidence C)
• Systemic corticosteroids: up to 5 days for moderate/severe (Evidence A)
• Antibiotics: 5-day course for purulent sputum, positive culture, or requiring mechanical ventilation (Evidence A/B)
• Methylxanthines: NOT recommended (increased side effects)

Ventilatory Support

• HFNT (High-Flow Nasal Therapy): First mode for acute hypoxemic failure; also if unable to tolerate NIV
• NIV: Indicated if PaCO₂ ≥ 45 mmHg + pH ≤ 7.35, or severe dyspnea with respiratory muscle fatigue, or persistent hypoxemia — reduces intubation, improves survival (Evidence A)
• Invasive MV: Life-threatening hypoxemia despite HFNT/NIV, cardiac arrest, refractory hemodynamic instability

Place of Care

• Ambulatory: Mild exacerbation, minimal comorbidities, cooperative, good home support
• Hospital: Signs of respiratory failure, failed initial treatment, serious comorbidities, insufficient home support
• ICU: Persistent hypoxemia/hypercapnia despite ventilator support, hemodynamic instability, altered consciousness

Post-Exacerbation Discharge

• Initiate/optimize LABD before discharge
• Consider ICS addition if eos ≥ 100 + ≥1 moderate/severe exacerbation
• Follow-up at 1–4 weeks and 12–16 weeks
• Reassess: inhaler technique, oxygen need, pulmonary rehab eligibility, spirometry (at 12–16 weeks), comorbidities

6. COPD and Multimorbidity

• Mentation: Screen for depression, anxiety, cognitive impairment (PHQ-2, GAD-2, MMSE)
• Medications: Review, de-prescribe if appropriate, minimize polypharmacy
• Mobility: Assess balance and exercise capacity (6MWT, SARC-F)
• Morbidities: Identify and address management

Key Morbidity Clusters

Notable Points

• CVD risk is significantly elevated during and up to 1 year after a moderate/severe exacerbation
• Annual LDCT for lung cancer screening in smokers with COPD; not recommended in non-smoker COPD without evidence
• OSA + COPD: CPAP treatment reduces mortality
• Low BMI (< 21 kg/m²) is an independent predictor of death
• GERD increases exacerbation risk

7. Artificial Intelligence & Emerging Technologies (NEW Chapter in 2026)

• AI applications: Diagnosis, clinical assessment, management guidance, prognosis prediction
• Risks: Misdiagnosis, bias, black-box models, data privacy, unclear accountability
• Mitigation: Rigorous validation, human oversight, interpretable models, equitable access
• Telehealth: Virtual/hybrid models may improve access and affordability; pulmonary rehab may be delivered virtually; evidence on virtual vs. in-person effectiveness still emerging

Key Updates in GOLD 2026 vs. Prior Editions